title: New potential anticancer agent of carborane derivatives: selective cellular interaction and activity of ferrocene-substituted dithio-o-carborane conjugates.
abstract: The large diversity of structures and unique bonding modes of organometallic complexes make them possible to act as promising candidate therapeutic agents. In this study, the new type of ferrocene-substituted dithio-o-carborane conjugates (FcSB1, FcSB2, and FcSBCO) has been synthesized, and their in vitro antineoplastic activities have been explored by means of the electrochemical study, the real time cell electronic sensing (RT-CES) system, and biological assays. The conjugate-cell interactions were first monitored by electrochemistry, and the results show different cell uptake efficiency for FcSB1, FcSB2, and FcSBCO toward target cells. Both the highly hydrophobic ferrocenyl and carboranyl groups render the conjugates able to rapidly enter cells and exert acute cytotoxicity after 4 h incubation in serum-free media. However, FcSB1, FcSB2, and FcSBCO display different inhibition efficiencies toward SMMC-7721 and HepG2 cancer cells via the G(0)/G(1) arrest mechanism in a physiological environment. The anticancer activity is in the order FcSB2 > FcSB1 > FcSBCO, which is parallel to the order of the redox potentials of the ferrocenyl groups in the three complexes. In particular, FcSB1 and FcSB2 display a potent selective inhibition effect on the proliferation of the cancer cell lines SMMC-7721 and HepG2, but almost no effect on the normal cell line, the human embryonic lung fibroblast (HELF) cells. Thus, these results may provide some clues for use of the ferrocene-carborane conjugates in developing anticancer drugs.
authors.affiliation: State Key Lab of Bioelectronics (Chien-Shiung Wu Lab), Southeast University, Jiangsu 210096, China.
authors.forename: Chunhui
authors.initials: C
authors.lastname: Wu
authors.forename: Hongde
authors.initials: H
authors.lastname: Ye
authors.forename: Wenjuan
authors.initials: W
authors.lastname: Bai
authors.forename: Qingning
authors.initials: Q
authors.lastname: Li
authors.forename: Dadong
authors.initials: D
authors.lastname: Guo
authors.forename: Gang
authors.initials: G
authors.lastname: Lv
authors.forename: Hong
authors.initials: H
authors.lastname: Yan
authors.forename: Xuemei
authors.initials: X
authors.lastname: Wang
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology*; D001896:Boron Compounds / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D015195:Drug Design; D004563:Electrochemistry; D005296:Ferrous Compounds / Q000737:chemistry*; D006801:Humans; D000075163:Metallocenes; D013329:Structure-Activity Relationship; D013379:Substrate Specificity; D013455:Sulfur / Q000737:chemistry*
chemical_list: D000970:Antineoplastic Agents; D001896:Boron Compounds; D005296:Ferrous Compounds; D000075163:Metallocenes; D013455:Sulfur; C004998:ferrocene